HUTCHMED (NASDAQ:HCM) Rating Increased to Buy at StockNews.com

HUTCHMED (NASDAQ:HCM) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of HUTCHMED in a research note on Friday, January 12th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, HUTCHMED has a consensus rating of “Moderate Buy” and a consensus target price of $29.70.

HUTCHMED Stock Performance

NASDAQ:HCM opened at $16.65 on Wednesday. The company has a quick ratio of 2.60, a current ratio of 2.72 and a debt-to-equity ratio of 0.06. HUTCHMED has a fifty-two week low of $10.68 and a fifty-two week high of $20.73. The stock’s 50-day moving average is $14.82 and its two-hundred day moving average is $16.61.

Institutional Investors Weigh In On HUTCHMED

Several institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in shares of HUTCHMED by 15.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 475,370 shares of the company’s stock valued at $8,609,000 after buying an additional 62,762 shares during the last quarter. FIL Ltd lifted its holdings in shares of HUTCHMED by 6.2% during the 4th quarter. FIL Ltd now owns 75,993 shares of the company’s stock valued at $1,376,000 after buying an additional 4,452 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of HUTCHMED during the 4th quarter valued at about $406,000. Sei Investments Co. acquired a new stake in shares of HUTCHMED during the 4th quarter valued at about $197,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of HUTCHMED during the 4th quarter valued at about $274,000. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.